Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.45 |
| ▸ | PIP5K1C | O60331 | 5/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
| ▸ | VCP | P55072 | 7/20 | 0.37 |
| ▸ | CDK7 | P50613 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655335 | 0.87 | PIP5K1C (0.44) | CHEK1PIP5K1CITKCDK7PARP1 | |
| SCHEMBL13655348 | 0.82 | PIP5K1C (0.40) | CHEK1PIP5K1CITKCDK7PARP1 | |
| SCHEMBL13655346 | 0.78 | CHEK1 (0.46) | CHEK1PIP5K1CCDK7 | |
| SCHEMBL13655332 | 0.76 | PIP5K1C (0.40) | CHEK1PIP5K1CCDK7 | |
| SCHEMBL13655330 | 0.76 | CLK2 (0.39) | CHEK1PIP5K1CCDK7 | |
| SCHEMBL13655325 | 0.76 | MC4R (0.40) | CHEK1PIP5K1CCDK7 | |
| SCHEMBL13655336 | 0.76 | CHEK1 (0.46) | CHEK1PIP5K1CCDK7PARP1 | |
| SCHEMBL13655345 | 0.75 | CLK2 (0.42) | CHEK1PIP5K1CITKCDK7PARP1 | |
| SCHEMBL13655342 | 0.74 | TERT (0.41) | CHEK1PIP5K1CITKCDK7PARP1 | |
| SCHEMBL13655331 | 0.74 | KDM4E (0.43) | CHEK1PIP5K1CITKCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | CHEK1 1733/4885PIP5K1C 1995/4885ITK 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.